Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sancuso for CINV prevention in CapeOX
NCT05325190Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05325190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325190.